166 related articles for article (PubMed ID: 33371043)
21. A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK.
Manalan K; Green N; Arnold A; Cooke GS; Dedicoat M; Lipman M; Loyse A; Harrison TS; Kon OM
J Infect; 2020 Jan; 80(1):38-41. PubMed ID: 31550466
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of All-Oral Regimens for the Treatment of Multidrug-Resistant Tuberculosis in Korea: Comparison With Conventional Injectable-Containing Regimens.
Park HY; Kwon JW; Kim HL; Kwon SH; Nam JH; Min S; Oh IS; Bea S; Choi SH
J Korean Med Sci; 2023 May; 38(21):e167. PubMed ID: 37270920
[TBL] [Abstract][Full Text] [Related]
23. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial.
Madan JJ; Rosu L; Tefera MG; van Rensburg C; Evans D; Langley I; Tomeny EM; Nunn A; Phillips PP; Rusen ID; Squire SB;
Bull World Health Organ; 2020 May; 98(5):306-314. PubMed ID: 32514196
[TBL] [Abstract][Full Text] [Related]
24. Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country.
Chesov D; Heyckendorf J; Alexandru S; Donica A; Chesov E; Reimann M; Crudu V; Botnaru V; Lange C
Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33334942
[TBL] [Abstract][Full Text] [Related]
25. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
Schnippel K; Firnhaber C; Page-Shipp L; Sinanovic E
Int J Tuberc Lung Dis; 2018 Aug; 22(8):918-925. PubMed ID: 29991402
[TBL] [Abstract][Full Text] [Related]
26. Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol.
Padmapriyadarsini C; Devaleenal B; Ponnuraja C; Ramraj B; Singla R; Parmar M; Mattoo S; Mandal S
BMJ Open; 2022 Aug; 12(8):e058606. PubMed ID: 36038181
[TBL] [Abstract][Full Text] [Related]
27. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
Chahine EB; Karaoui LR; Mansour H
Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
[TBL] [Abstract][Full Text] [Related]
28. mHealth application for improving treatment outcomes for patients with multidrug-resistant tuberculosis in Vietnam: an economic evaluation protocol for the V-SMART trial.
Cheng Q; Dang T; Nguyen TA; Velen K; Nguyen VN; Nguyen BH; Vu DH; Long CH; Do TT; Vu TM; Marks GB; Yapa M; Fox GJ; Wiseman V
BMJ Open; 2023 Dec; 13(12):e076778. PubMed ID: 38081668
[TBL] [Abstract][Full Text] [Related]
29. World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward.
Van Deun A; Decroo T; Tahseen S; Trébucq A; Schwoebel V; Ortuno-Gutierrez N; de Jong BC; Rieder HL; Piubello A; Chiang CY
Int J Antimicrob Agents; 2020 Jan; 55(1):105822. PubMed ID: 31626907
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea.
Park HY; Ku HM; Sohn HS; Seo HS; Yung Lee H; Hwa Lim K; Kwon JW
Clin Ther; 2016 Mar; 38(3):655-67.e1-2. PubMed ID: 26907504
[TBL] [Abstract][Full Text] [Related]
31. Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China.
Agnarson AM; Wang XC; Potluri R; Bhandari H; Dhir A; Kambili C; Metz L
BMC Infect Dis; 2020 Feb; 20(1):113. PubMed ID: 32041542
[TBL] [Abstract][Full Text] [Related]
32. Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis.
Goodall RL; Sanders K; Bronson G; Gurumurthy M; Torrea G; Meredith S; Nunn A; Rusen ID;
Trials; 2022 Jun; 23(1):474. PubMed ID: 35672833
[TBL] [Abstract][Full Text] [Related]
33. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
Laurence YV; Griffiths UK; Vassall A
Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
[TBL] [Abstract][Full Text] [Related]
34. Current and developing therapies for the treatment of multi drug resistant tuberculosis (MDR-TB) in India.
Muniyandi M; Ramachandran R
Expert Opin Pharmacother; 2017 Sep; 18(13):1301-1309. PubMed ID: 28786691
[TBL] [Abstract][Full Text] [Related]
35. Modeling the impact of bedaquiline treatment strategies on the multidrug-resistant tuberculosis burden in India.
Mehra M; Kambili C; Potluri R; Rhines A; Singh V; Thomas A
Int J Tuberc Lung Dis; 2017 Aug; 21(8):902-909. PubMed ID: 28786799
[TBL] [Abstract][Full Text] [Related]
36. Economic implications of novel regimens for tuberculosis treatment in three high-burden countries: a modelling analysis.
Ryckman TS; Schumacher SG; Lienhardt C; Sweeney S; Dowdy DW; Mirzayev F; Kendall EA
Lancet Glob Health; 2024 Jun; 12(6):e995-e1004. PubMed ID: 38762299
[TBL] [Abstract][Full Text] [Related]
37. Cost of treatment support for multidrug-resistant tuberculosis using patient-centred approaches in Ethiopia: a model-based method.
Rosu L; Morgan L; Tomeny EM; Worthington C; Jin M; Nidoi J; Worthington D
Infect Dis Poverty; 2023 Jul; 12(1):65. PubMed ID: 37420269
[TBL] [Abstract][Full Text] [Related]
38. Treatment Outcomes of Patients Switching From an Injectable Drug to Bedaquiline During Short Standardized Treatment for Multidrug-resistant Tuberculosis in Mozambique.
Bastard M; Molfino L; Mutaquiha C; Galindo MA; Zindoga P; Vaz D; Mahinça I; DuCros P; Rusch B; Telnov A
Clin Infect Dis; 2019 Oct; 69(10):1809-1811. PubMed ID: 30901021
[TBL] [Abstract][Full Text] [Related]
39. Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis.
Fu L; Weng T; Sun F; Zhang P; Li H; Li Y; Yang Q; Cai Y; Zhang X; Liang H; Chen X; Wang Z; Liu L; Zhang W; Deng G
Int J Infect Dis; 2021 Oct; 111():138-147. PubMed ID: 34454119
[TBL] [Abstract][Full Text] [Related]
40. Harnessing new mHealth technologies to Strengthen the Management of Multidrug-Resistant Tuberculosis in Vietnam (V-SMART trial): a protocol for a randomised controlled trial.
Velen K; Nguyen VN; Nguyen BH; Dang T; Nguyen HA; Vu DH; Do TT; Pham Duc C; Nguyen HL; Pham HT; Marais BJ; Johnston J; Britton W; Beardsley J; Negin J; Wiseman V; Marks GB; Nguyen TA; Fox GJ
BMJ Open; 2022 Jun; 12(6):e052633. PubMed ID: 35732397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
